FutureChem, a Korea-based radiopharmaceutical company, presented interim results from its phase 2 clinical trial for FC705, a prostate cancer treatment radiopharmaceutical candidate, at the Asia-Pacific Prostate Society (APPS) Conference in Hawaii, running from last Saturday to Friday.

The APPS serves as a platform for urologists to share basic and clinical research on prostate health and disease.

The study evaluated the safety and efficacy of FC705 in patients with metastatic castration-resistant prostate cancer (mCRPC) at Seoul St. Mary’s Hospital. Participants received up to six doses of 100 mCi of FC705 at eight-week intervals.

As a result, despite FC705 being administered alone, the treatment achieved a PSA reduction rate of over 50 percent, surpassing other radiopharmaceuticals with the same mechanism of action.

Of the total 11 patients experiencing adverse events, most effects were mild to moderate. Specifically, three patients experienced Grade 1 events, three had Grade 2 events, and five reported Grade 3 events, with no cases of Grade 4 or 5 adverse events reported.

The company stressed that the adverse event profile indicates a safer therapeutic option, with the Grade 3 or higher adverse event rate standing at a low 25 percent, a significant advantage compared to similar therapies.

FutureChem is currently consolidating further data on the overall response rate (ORR), expecting FC705 to show top-tier results. The company is also exploring combination trials with multinational pharmaceutical partners, testing FC705 alongside existing anticancer agents.

Looking ahead, FutureChem aims to complete a clinical study report (CSR) for FC705 by the first quarter of 2025, and aims to initiate phase 3 trials in Korea and apply for conditional approval in the first half of next year.